WO2001010387A3 - Antiviral therapy use of P-glycoprotein modulators - Google Patents

Antiviral therapy use of P-glycoprotein modulators Download PDF

Info

Publication number
WO2001010387A3
WO2001010387A3 PCT/US2000/040588 US0040588W WO0110387A3 WO 2001010387 A3 WO2001010387 A3 WO 2001010387A3 US 0040588 W US0040588 W US 0040588W WO 0110387 A3 WO0110387 A3 WO 0110387A3
Authority
WO
WIPO (PCT)
Prior art keywords
protease inhibitor
antiviral therapy
methanodibenzosuberane
therapy use
glycoprotein modulators
Prior art date
Application number
PCT/US2000/040588
Other languages
French (fr)
Other versions
WO2001010387A2 (en
Inventor
Alastair J J Wood
Richard B Kim
Grant R Wilkinson
Original Assignee
Univ Vanderbilt
Wood Alastair J
Richard B Kim
Grant R Wilkinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt, Wood Alastair J, Richard B Kim, Grant R Wilkinson filed Critical Univ Vanderbilt
Priority to AU77574/00A priority Critical patent/AU7757400A/en
Priority to JP2001514912A priority patent/JP2003523944A/en
Priority to EP00967364A priority patent/EP1202737A4/en
Priority to CA002378984A priority patent/CA2378984A1/en
Publication of WO2001010387A2 publication Critical patent/WO2001010387A2/en
Publication of WO2001010387A3 publication Critical patent/WO2001010387A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to a pharmaceutical composition comprising a 10, 11 methanodibenzosuberane and use thereof for the treatment of HIV infection. Co-administration of the 10, 11 methanodibenzosuberane with an HIV protease inhibitor increases the concentration of the protease inhibitor in certain tissues, including the brain and testes, without substantially increasing plasma levels of the protease inhibitor. Accordingly, additional antiviral therapy can be achieved without use of increased drug dosages, thereby reducing the potential for occurrence of undesirable side effects deriving from drug toxicity.
PCT/US2000/040588 1999-08-09 2000-08-07 Antiviral therapy use of p-glycoprotein modulators WO2001010387A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU77574/00A AU7757400A (en) 1999-08-09 2000-08-07 Antiviral therapy use of p-glycoprotein modulators
JP2001514912A JP2003523944A (en) 1999-08-09 2000-08-07 Antiviral therapy using P-glycoprotein modifiers
EP00967364A EP1202737A4 (en) 1999-08-09 2000-08-07 Antiviral therapy use of p-glycoprotein modulators
CA002378984A CA2378984A1 (en) 1999-08-09 2000-08-07 Antiviral therapy use of p-glycoprotein modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37026699A 1999-08-09 1999-08-09
US09/370,266 1999-08-09

Publications (2)

Publication Number Publication Date
WO2001010387A2 WO2001010387A2 (en) 2001-02-15
WO2001010387A3 true WO2001010387A3 (en) 2001-08-23

Family

ID=23458912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/040588 WO2001010387A2 (en) 1999-08-09 2000-08-07 Antiviral therapy use of p-glycoprotein modulators

Country Status (5)

Country Link
EP (1) EP1202737A4 (en)
JP (1) JP2003523944A (en)
AU (1) AU7757400A (en)
CA (1) CA2378984A1 (en)
WO (1) WO2001010387A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6398199B1 (en) 1999-09-03 2002-06-04 Barber Manufacturing Company, Inc. Coil spring assembly
DE60124080T2 (en) 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco COMPOUNDS AND METHOD FOR THE TREATMENT OF ALZHEIMER'S DISEASE
ATE396174T1 (en) 2001-06-01 2008-06-15 Elan Pharm Inc HYDROXYALKYLAMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THE USE THEREOF FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SIMILAR DISEASES
MXPA03011521A (en) 2001-06-13 2004-03-18 Elan Pharm Inc Aminediols as agents for the treatment of alzheimer's disease.
US7067542B2 (en) 2001-07-10 2006-06-27 Pharmacia & Upjohn Company Diaminediols for the treatment of Alzheimer's disease
CA2453451A1 (en) 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Aminediols for the treatment of alzheimer's disease
BR0213139A (en) 2001-10-04 2004-08-10 Elan Pharm Inc Compound, method of treating or preventing disease and preparing a compound, use of a compound and pharmaceutical composition
NZ533107A (en) 2001-11-08 2007-04-27 Upjohn Co N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
EP1453788A1 (en) 2001-12-06 2004-09-08 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
WO2004058686A1 (en) 2002-04-30 2004-07-15 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer’s disease
EP1615892A2 (en) 2003-04-21 2006-01-18 Elan Pharmaceuticals, Inc. Benzamide 2-hydroxy-3-diaminoalkanes
WO2005087751A2 (en) 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
JP2007533741A (en) 2004-04-22 2007-11-22 イーライ リリー アンド カンパニー BACE inhibitor
US7385085B2 (en) 2004-07-09 2008-06-10 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
JP2011231127A (en) * 2011-08-01 2011-11-17 Sekisui Medical Co Ltd Preparation for improving oral absorption and pharmaceutical composition utilizing the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5939456A (en) * 1996-07-26 1999-08-17 Perrine; Susan P. Pulsed administration of compositions for the treatment of blood disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5939456A (en) * 1996-07-26 1999-08-17 Perrine; Susan P. Pulsed administration of compositions for the treatment of blood disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1202737A4 *

Also Published As

Publication number Publication date
WO2001010387A2 (en) 2001-02-15
CA2378984A1 (en) 2001-02-15
AU7757400A (en) 2001-03-05
EP1202737A2 (en) 2002-05-08
JP2003523944A (en) 2003-08-12
EP1202737A4 (en) 2005-03-02

Similar Documents

Publication Publication Date Title
AU7445901A (en) Pharmaceutical compositions comprising cannabidiol derivatives
WO2001010387A3 (en) Antiviral therapy use of P-glycoprotein modulators
WO2004002999A3 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
WO2004026303A3 (en) Use of posaconazole for the treatment of fungal infections
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
NO954996L (en) Use of nona and decapeptides for the manufacture of a medicament for the treatment of AIDS
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2002078627A3 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
MXPA03008623A (en) Pharmaceutical combinations for the treatment of cancer.
SG147485A1 (en) Pharmaceutical compositions for prevention of overdose or abuse
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
MXPA04005425A (en) Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer.
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
WO2002007721A3 (en) Use of cox-2 inhibitors for preventing immunodeficiency
NZ514558A (en) Viral treatment
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
ZA991029B (en) Composition and methods for treatment of hiv infections.
BR0307022A (en) Method of treating a patient who needs analgesia
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
CA2414586A1 (en) Agent for therapeutic treatment of optic nerve diseases and the like
WO2001010454A3 (en) Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10031827

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2378984

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000967364

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000967364

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000967364

Country of ref document: EP